Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ruixiao Wang

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Related publications

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology

Oncology

2012

English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

English

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Journal of Thoracic Oncology

English

Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Non-Invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer

Experimental Hematology and Oncology

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer With EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study

Journal of Thoracic Oncology

English

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer

Cancer Research

Oncology

2020

English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ruixiao Wang

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Related publications

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Non-Invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer With EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation